A case report: Response to Osimertinib in non-small cell lung cancer patient with uncommon EGFR mutation
Background: The epidermal growth factor receptor (EGFR) gene harbors a variety of pathogenic variants in non-small cell lung cancer (NSCLC) with several mutations within exons 18–21 serving as common targets for tyrosine kinase inhibitor (TKI) therapy. Osimertinib is a third generation TKI that was...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-12-01
|
| Series: | Current Problems in Cancer: Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666621922000527 |